Get the Stockscreener App
87.87
4.81%
-4.44
After Hours:
88.01
0.14
+0.16%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $87.87, with a volume of 20.48M.
It is down -4.81% in the last 24 hours and down -3.89% over the past month.
See More
Previous Close:
$92.31
Open:
$92.31
24h Volume:
20.48M
Relative Volume:
1.45
Market Cap:
$235.20B
Revenue:
$64.17B
Net Income/Loss:
$17.12B
P/E Ratio:
13.06
EPS:
6.73
Net Cash Flow:
$18.10B
1W Performance:
-7.23%
1M Performance:
-3.89%
6M Performance:
-23.41%
1Y Performance:
-29.88%
1-Day Range:
$87.08
$92.31
1-Week Range:
$87.08
$95.43
52-Week Range:
$81.04
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
87.87 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
852.35 | 765.56B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.34 | 355.44B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
73.60 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck Doubles Down On Oral Lipid-Lowering Drugs With Hengrui’s Lp(a) Asset - Scrip
Why Pharma and Biotech Stocks Got Thrashed on Tuesday - The Motley Fool
Is Merck & Co. Inc. (MRK) The Best Defensive Stock Amid Market Volatility? - Insider Monkey
Merck Makes Bold $2B Bet on Chinese Cardio Drug - USA Herald
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors - MSN
For nearly $2B, Jiangsu Hengrui licenses heart drug to Merck - BioWorld Online
Merck Betting Up To $2B On China-Developed Cardio Drug - Law360
Merck & Co Inc (MRK) Trading Down 3.66% on Mar 25 - GuruFocus.com
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment - Benzinga
Merck Strikes Nearly $2 Billion Licensing Deal For Chinese Firm's Heart Disease Drug Candidate - Marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck inks $2B licensing deal with Jiangsu Hengrui (MRK:NYSE) - Seeking Alpha
Merck Will Pay Up to $2 Billion for Chinese Heart Drug Rights - Bloomberg
Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Merck buys rights to heart disease drug in latest China deal - Marketscreener.com
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. - Business Wire
Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Merck & Co. sees ratings upgrade to Aa3 by Moody’s Ratings - Investing.com
Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (Fed. Cir. 2025) - JD Supra
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein - GlobeNewswire
Is Merck & Co. (MRK) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
MRK LAWSUIT ALERT: The Gross Law Firm Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - TradingView
Merck & Co. (MRK): Among Stocks Insiders Were Piling Into Recently - Yahoo Finance
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - PR Newswire
Lyophilized Product Market to Witness Remarkable Growth with - openPR
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRK - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - PR Newswire
Merck & Co., Inc. (MRK): Among Incredibly Cheap Dividend Stock to Buy Now - Insider Monkey
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
Why Merck & Co. (MRK) Is Among the Most Undervalued Biotech Stocks to Invest In - Yahoo Finance
Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsMRK - ACCESS Newswire
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Markets Insider
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Merck & Co's Options: A Look at What the Big Money is Thinking - Benzinga
Class Action Filed Against Merck & Co., Inc. (MRK)April 14, 2025 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued S&P 500 Stock to Buy Now? - Yahoo Finance
Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025MRK - PR Newswire
Is Merck & Co Inc. (NYSE:MRK) the Most Profitable Value Stock to Buy Now? - Insider Monkey
Shareholders that lost money on Merck & Co., Inc.(MRK) - GlobeNewswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):